Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Operating Expenses (2016 - 2025)

Voyager Therapeutics' Operating Expenses history spans 11 years, with the latest figure at $45.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.55% year-over-year to $45.3 million; the TTM value through Dec 2025 reached $172.2 million, up 5.47%, while the annual FY2025 figure was $172.2 million, 5.47% up from the prior year.
  • Operating Expenses for Q4 2025 was $45.3 million at Voyager Therapeutics, up from $44.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $45.3 million in Q4 2025 and bottomed at $20.1 million in Q2 2022.
  • The 5-year median for Operating Expenses is $33.1 million (2021), against an average of $33.3 million.
  • The largest annual shift saw Operating Expenses plummeted 32.94% in 2022 before it soared 56.42% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $22.4 million in 2021, then increased by 2.87% to $23.0 million in 2022, then skyrocketed by 56.42% to $36.0 million in 2023, then rose by 23.83% to $44.6 million in 2024, then rose by 1.55% to $45.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Operating Expenses are $45.3 million (Q4 2025), $44.0 million (Q3 2025), and $41.8 million (Q2 2025).